Signos Safety, Regulation & Compliance: An Evidence-Based Assessment

What Signos Actually Is (and What It Is Not)

Signos markets itself as a CGM-powered weight-loss system. Members receive an Abbott FreeStyle Libre 3 sensor, wear it continuously, and use the Signos app to receive personalized glucose-stabilization targets and food-response feedback. The platform does not prescribe medications. It does not offer GLP-1 agonists, metformin, or any other pharmacotherapy through its core subscription.

That distinction matters for understanding the safety and regulatory profile. The hardware component, the Abbott FreeStyle Libre 3, carries FDA 510(k) clearance as a Class II medical device for continuous glucose monitoring [1]. The software layer, Signos's coaching algorithm, is a wellness application and does not carry an independent FDA clearance or approval as a medical device or drug product.

FDA Regulatory Status of the Hardware

The FreeStyle Libre 3 received FDA clearance in May 2022. Abbott's original FreeStyle Libre system was cleared in 2017 under 510(k) K162026 [1]. Cleared Class II CGM devices must demonstrate substantial equivalence to a predicate device and meet performance specifications for mean absolute relative difference (MARD), which the Libre 3 meets at approximately 7.8% MARD across the labeled wear period [2].

Regulatory Status of the App and Coaching Layer

The Signos coaching app does not appear on the FDA's 510(k) database as a cleared software-as-a-medical-device (SaMD) product. Under FDA's 2019 Digital Health Software Precertification framework and the 21st Century Cures Act, certain wellness apps that do not make diagnostic or treatment claims are not required to seek clearance [3]. Signos occupies this wellness category. Clinicians and prospective users should understand that the coaching recommendations are not validated as a standalone medical treatment.

CGM Accuracy and Device Safety

The underlying sensor Signos deploys has a well-characterized performance and safety record. Accuracy and local tolerability are the two main safety dimensions.

Sensor Accuracy in Real-World Use

A 2020 real-world study published in Diabetes Technology & Therapeutics evaluated the FreeStyle Libre system and found mean MARD values of 9.2% in a community sample, slightly higher than the controlled-trial figure of approximately 7.8% [2]. For context, the FDA threshold for CGM accuracy is a MARD <15% [4]. The Libre 3 consistently performs within FDA specifications, though individual sensor-to-sensor variation exists.

Accuracy is lower during the first 60 minutes after sensor application (the warm-up period) and during periods of rapid glucose change exceeding 2 mg/dL per minute [2]. Users who make food decisions solely based on interstitial glucose readings during these windows could misinterpret transient artifacts as true postprandial spikes.

Skin and Local Reactions

Adhesive-related skin reactions are the most common adverse event associated with CGM use. A 2021 systematic review in Diabetes Care identified contact dermatitis or adhesive reactions in approximately 3% of CGM wearers, with most cases resolving on removal [5]. Signos's sensor is worn on the upper arm for up to 14 days per session. No systemic safety risks are associated with the sensor itself under normal use conditions.

The Evidence Base for CGM-Guided Weight Loss

This is where an honest assessment diverges from Signos's marketing claims. The question is not whether CGM hardware is safe or accurate. It is whether wearing a CGM and following glucose-stabilization coaching produces clinically meaningful weight loss in adults without diabetes.

Evidence in People Without Diabetes

A 2022 randomized controlled trial published in JAMA Internal Medicine (N=153) assigned adults with overweight or obesity but without diabetes to CGM-guided dietary coaching versus standard dietary advice over 8 weeks. The CGM group lost 1.5 kg versus 1.4 kg in the control group, a difference that did not reach statistical significance (P<0.38) [6]. The authors concluded that CGM feedback alone did not produce superior weight loss compared to standard coaching in this non-diabetic population.

A separate 2023 study in Nutrients (N=120) examined continuous glucose monitoring combined with a structured low-glycemic diet over 12 weeks and found a 3.1 kg reduction in body weight in the CGM group versus 2.4 kg in the dietary-advice-only group. The difference was statistically significant (P<0.04), but the absolute gap was modest [7].

Evidence in Prediabetes and Metabolic Syndrome

The evidence base is stronger for people with prediabetes or metabolic syndrome. A 2021 trial in Diabetes Care (N=203) found that CGM-guided lifestyle intervention reduced HbA1c by 0.31 percentage points and body weight by 3.8 kg over 24 weeks in adults with prediabetes, compared to 0.12 percentage points and 1.9 kg in the standard-care arm (P<0.01 for both endpoints) [8]. This population likely aligns with the higher-tier Signos subscription target.

Comparison With GLP-1 Pharmacotherapy

For context on effect size, STEP-1 (N=1,961) showed that semaglutide 2.4 mg subcutaneous weekly produced 14.9% mean body-weight loss at 68 weeks versus 2.4% with placebo [9]. The CGM-guided lifestyle trials cited above produced weight reductions in the range of 2 to 4 kg absolute, which translates to roughly 2 to 4% of body weight in a 100 kg individual. CGM coaching and GLP-1 pharmacotherapy are not competing in the same efficacy bracket, though they may complement each other in a multimodal program.

Is Signos Legit? Compliance, Privacy, and Business Practices

"Legit" covers several distinct questions: Is the company licensed? Does it protect user data? Does it make false claims?

Business and Licensing Status

Signos Health Inc. Is a registered corporation headquartered in San Francisco, California. The company operates a telehealth partner model to support sensor dispensing in states that require a prescription for CGM sensors. This model is consistent with applicable state telehealth regulations. The FDA's enforcement posture on wellness CGM platforms has not resulted in any public warning letters or consent decrees against Signos as of the date of this review [3].

Data Privacy

Signos's glucose and behavioral data constitute health information. The platform collects continuous biometric data 24 hours per day during sensor wear. Users should review whether Signos is covered under HIPAA as a Business Associate or operates under a separate consumer privacy policy. Consumer wellness apps that are not covered entities under HIPAA are governed by the FTC Act rather than HIPAA's stricter protections [10]. The FTC issued a Health Breach Notification Rule update in 2023 specifically to address consumer health apps [10].

Marketing Claims

Signos markets outcomes including weight loss, blood sugar stabilization, and metabolic improvement. These claims fall under FTC jurisdiction. The company's website uses language consistent with wellness positioning rather than disease treatment claims, which keeps it outside FDA drug-advertising regulations. Prospective users should apply normal skepticism to before-and-after testimonials; as noted above, the RCT evidence for CGM-guided weight loss in metabolically healthy adults is modest [6].

Signos vs. Alternatives: A Clinical Comparison

Clinicians evaluating where Signos fits in a weight-management plan should consider the following patient-selection framework.

CGM-Only Platforms (e.g., Levels Health, Nutrisense)

Signos competes directly with Levels Health and Nutrisense, both of which offer CGM-plus-app subscriptions at similar price points ($200 to $400 per month). None of these platforms have published head-to-head randomized trials comparing their algorithms. The hardware they all use, Abbott Libre or Dexterity G7, carries FDA clearance regardless of which app sits on top. The differentiator is the coaching algorithm and user interface, neither of which has been independently validated in peer-reviewed trials for any of these companies.

GLP-1 Telehealth Programs

Platforms such as Ro, Hims & Hers, and HealthRX-affiliated programs that prescribe semaglutide (Ozempic/Wegovy) or tirzepatide (Zepbound/Mounjaro) operate under a prescription drug model regulated by the DEA, state medical boards, and FDA. The pharmacotherapy evidence base is far larger. SURMOUNT-1 (N=2,539) found tirzepatide 15 mg produced 20.9% mean weight loss at 72 weeks [11]. CGM subscription services and GLP-1 prescribing services are fundamentally different regulatory and clinical categories.

Structured Diabetes Prevention Programs

The CDC-recognized National Diabetes Prevention Program (DPP) is a 12-month lifestyle intervention with a 5 to 7% weight-loss evidence base in prediabetic adults, at a cost typically covered by Medicare and many commercial insurers [12]. For users who qualify for DPP, the cost-effectiveness calculation relative to a $399/month CGM subscription is worth discussing with a clinician.

Adverse Events and Safety Profile: What the Data Show

Because Signos does not prescribe medication, the pharmacological adverse-event profile of GLP-1 agents (nausea, vomiting, pancreatitis risk, potential thyroid C-cell effects) is not applicable here. The safety considerations are narrower.

Sensor-Related Events

As described above, skin reactions affect approximately 3% of CGM users [5]. Users with known adhesive allergies should use a barrier wipe or consult a dermatologist before initiating sensor wear. Rare cases of sensor breakage under the skin have been reported to the FDA's MAUDE database for CGM devices generally, though Abbott has not received a device recall for the Libre 3 system as of this article's review date [1].

Behavioral Safety Considerations

A more under-discussed risk of CGM use in non-diabetic populations is glucose anxiety. A 2023 paper in Diabetic Medicine (N=84 adults without diabetes) found that 18% of participants reported increased anxiety about food choices and 9% reported disordered eating cognitions after 4 weeks of CGM wear [13]. The American Diabetes Association's 2024 Standards of Care note that CGM use in non-diabetic individuals lacks a defined clinical protocol and that interpretation support is needed to avoid misattribution of normal glycemic variability as pathological [14].

No Drug Interactions

Because Signos does not dispense pharmacotherapy, drug interaction screening is not a safety requirement for the platform itself. Users who are concurrently prescribed metformin, insulin, or GLP-1 agonists through a separate provider should inform that provider of their CGM use, as postprandial glucose targets and hypoglycemia awareness counseling may differ.

Cost, Access, and Insurance Coverage

Signos charges approximately $399 per month, which includes the Abbott FreeStyle Libre 3 sensors and app access. The company offers a lower-tier plan at roughly $199 per month with fewer sensors per cycle.

Insurance coverage for CGM devices in non-diabetic, non-prediabetic adults is generally not available through Medicare or most commercial plans. CMS covers CGM for people with diabetes who meet specific criteria under LCD L33822 [15]. People with a formal prediabetes diagnosis (fasting glucose 100 to 125 mg/dL or HbA1c 5.7 to 6.4%) may qualify for CGM under some commercial plans if prescribed by a physician.

At $399 per month, 12 months of Signos costs $4,788. For comparison, a 68-week course of semaglutide 2.4 mg (Wegovy) at list price runs approximately $16,000 to $17,000 before insurance, though GLP-1 prescriptions are increasingly covered by employer plans. The CDC DPP, where covered by insurance, may cost the patient $0 to $200 total for the year [12].

What Clinicians and Patients Should Know Before Enrolling

Signos is not a scam. The hardware is FDA-cleared, the company is operating within applicable regulations, and the coaching approach has a plausible biological mechanism via postprandial glycemic feedback. The gaps are in the independent clinical-outcome evidence, the cost-effectiveness calculation for metabolically healthy adults, and the absence of pharmacist or physician oversight within the subscription itself.

Patients with prediabetes, metabolic syndrome, or existing insulin resistance have the strongest evidence base for benefit [8]. Patients who are metabolically healthy but want glucose biofeedback for athletic performance or general curiosity should understand that the weight-loss data in that population do not show meaningful superiority over structured dietary coaching alone [6].

Any prospective user currently taking glucose-lowering medications should discuss CGM target interpretation with their prescribing clinician before starting. Normal postprandial glucose peaks in non-diabetic adults can reach 140 mg/dL transiently without pathological significance; the American Diabetes Association's 2024 Standards of Care define the postprandial target for people with diabetes as <180 mg/dL one hour after eating [14], and non-diabetic thresholds are not yet defined by a consensus guideline.